gamma-aminobutyric acid has been researched along with Epilepsy, Partial, Sensory in 3 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Epilepsy, Partial, Sensory: A disorder characterized by recurrent focal onset seizures which have sensory (i.e., olfactory, visual, tactile, gustatory, or auditory) manifestations. Partial seizures that feature alterations of consciousness are referred to as complex partial seizures (EPILEPSY, COMPLEX PARTIAL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pregabalin is the first drug to receive approved labeling from the Food and Drug Administration (FDA) for the treatment of painful diabetic neuropathy and postherpetic neuralgia and is the first antiepileptic agent to receive FDA-approved labeling since 1999." | 8.84 | Pregabalin: an antiepileptic agent useful for neuropathic pain. ( Blommel, AL; Blommel, ML, 2007) |
| "Pregabalin may be beneficial for the treatment of neuropathic pain or partial-onset seizures in patients who do not respond to conventional treatments or cannot tolerate their adverse effects." | 8.84 | Pregabalin: an antiepileptic agent useful for neuropathic pain. ( Blommel, AL; Blommel, ML, 2007) |
| "The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of pregabalin are reviewed." | 6.44 | Pregabalin: an antiepileptic agent useful for neuropathic pain. ( Blommel, AL; Blommel, ML, 2007) |
| " The starting dosage for patients with neuropathic pain associated with diabetic peripheral neuropathy is 50 mg three times daily and may be increased to 300 mg daily within one week based on efficacy and tolerability." | 6.44 | Pregabalin: an antiepileptic agent useful for neuropathic pain. ( Blommel, AL; Blommel, ML, 2007) |
| "Pregabalin is the first drug to receive approved labeling from the Food and Drug Administration (FDA) for the treatment of painful diabetic neuropathy and postherpetic neuralgia and is the first antiepileptic agent to receive FDA-approved labeling since 1999." | 4.84 | Pregabalin: an antiepileptic agent useful for neuropathic pain. ( Blommel, AL; Blommel, ML, 2007) |
| "Pregabalin may be beneficial for the treatment of neuropathic pain or partial-onset seizures in patients who do not respond to conventional treatments or cannot tolerate their adverse effects." | 4.84 | Pregabalin: an antiepileptic agent useful for neuropathic pain. ( Blommel, AL; Blommel, ML, 2007) |
| "Gabapentin was well tolerated in patients with uncontrolled partial seizures up to 6 months of therapy." | 2.71 | Pharmacokinetics of gabapentin in paediatric patients with uncontrolled seizures. ( Lo, W; Nahata, MC; Tallian, KB; Tsao, CY, 2004) |
| " Pharmacokinetic parameters for gabapentin were determined by non-compartment methods using multivariate regression analysis." | 2.71 | Pharmacokinetics of gabapentin in paediatric patients with uncontrolled seizures. ( Lo, W; Nahata, MC; Tallian, KB; Tsao, CY, 2004) |
| "Data from nine patients were suitable for pharmacokinetic analysis." | 2.71 | Pharmacokinetics of gabapentin in paediatric patients with uncontrolled seizures. ( Lo, W; Nahata, MC; Tallian, KB; Tsao, CY, 2004) |
| "The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of pregabalin are reviewed." | 2.44 | Pregabalin: an antiepileptic agent useful for neuropathic pain. ( Blommel, AL; Blommel, ML, 2007) |
| " The starting dosage for patients with neuropathic pain associated with diabetic peripheral neuropathy is 50 mg three times daily and may be increased to 300 mg daily within one week based on efficacy and tolerability." | 2.44 | Pregabalin: an antiepileptic agent useful for neuropathic pain. ( Blommel, AL; Blommel, ML, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burd, SG | 1 |
| Krikova, EV | 1 |
| Badalian, OL | 1 |
| Chukanova, AS | 1 |
| Avakian, GG | 1 |
| Tallian, KB | 1 |
| Nahata, MC | 1 |
| Lo, W | 1 |
| Tsao, CY | 1 |
| Blommel, ML | 1 |
| Blommel, AL | 1 |
2 reviews available for gamma-aminobutyric acid and Epilepsy, Partial, Sensory
| Article | Year |
|---|---|
[Pregabalin in the polytherapy of partial epilepsy].
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy, Partial, Sensory; gamma-Aminobutyric Ac | 2009 |
Pregabalin: an antiepileptic agent useful for neuropathic pain.
Topics: Animals; Anticonvulsants; Diabetic Neuropathies; Epilepsy, Partial, Sensory; gamma-Aminobutyric Acid | 2007 |
1 trial available for gamma-aminobutyric acid and Epilepsy, Partial, Sensory
| Article | Year |
|---|---|
Pharmacokinetics of gabapentin in paediatric patients with uncontrolled seizures.
Topics: Adolescent; Amines; Anticonvulsants; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Dose-Resp | 2004 |